Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sellas Life Sciences Group

www.sellaslifesciences.com

Latest From Allecra Therapeutics GMBH

Venture Funding Deals, July 2016

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.

BioPharmaceutical Medical Device

VC Roundup: Annexon, Mersana Benefit As Investors Favor Private Over Public Biotechs

During a month when only two biotechnology companies have gone public, private drug developers continue to raise hundreds of millions of dollars in venture capital.

Companies Business Strategies

Nosopharm SAS

Nosopharm SAS aims to address bacterial multidrug resistance to antibiotics, particularly in hospital-acquired gram-negative infections, using an-house drug discovery platform that exploits the microbial diversity of the bacterial genera Xenorhabdus and Photorhabdus.

BioPharmaceutical

Recent Financings Of Private Companies, May 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging biopharma, medtech, and diagnostic life science companies that have received venture funding.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sellas Life Sciences Group
  • Senior Management
  • Angelos Stergiou, MD, Chmn. & CEO
    William Pollett, CFO
    Nicholas Sarlis, MD, PhD, SVP, CMO
    Martin G Baum, COO
  • Contact Info
  • Sellas Life Sciences Group
    315 Madison Ave.
    4th Fl.
    New York, NY 10017
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register